Month: October 2022

Branco, Luis C.; Serbanovic, Ana; Nunes da Ponte, Manuel; Afonso, Carlos A. M. published the artcile< Clean osmium-catalyzed asymmetric dihydroxylation of olefins in ionic liquids and supercritical CO2 product recovery>, Application In Synthesis of 112-63-0, the main research area is asym dihydroxylation olefin ionic liquid osmium catalyst.

The combination of ionic liquids (ILs) as solvents in the asym. Sharpless dihydroxylation (AD) with the use of scCO2 in the separation process allows a simple, efficient, clean and robust system for the reuse of the AD catalytic system, which also does not need the use of organic solvents either for the reaction or for the separation of products and allows the isolation of the diol, in high yield and enantiomeric excess and basically without contamination with osmium. The AD reaction was performed with the substrates 1-hexene and styrene, using the catalytic system consisting of (DHQD)2PHAL (1.0 mol% ) and K2OsO2(OH)4 (0.5 mol% ) and the co-oxidants K3Fe(CN)6 and N-methylmorpholine oxide (NMO). Under these conditions, a range of ILs based on the methylimidazolium (mim), dimethylimidazolium (bdmim) and tetraalkyldimethylguanidinium (dmg) cations were screened.

Chemical Communications (Cambridge, United Kingdom) published new progress about Dihydroxylation catalysts, stereoselective. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Application In Synthesis of 112-63-0.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

DerSarkissian, Maral; Bhak, Rachel H.; Oglesby, Alan; Priest, Julie; Gao, Emily; Macheca, Monica; Sharperson, Camara; Duh, Mei Sheng published the artcile< Retrospective analysis of comorbidities and treatment burden among patients with HIV infection in a US Medicaid population>, Formula: C19H34O2, the main research area is HIV infection cardiovascular disease hypertension asthma comorbidity antiretroviral therapy; Antiretroviral therapy; HIV burden; comorbidity; concomitant medication; pill burden.

Comorbidities and comedications are important factors influencing optimal therapy because people are living longer with HIV infection. This study describes the long-term comorbidity profile and treatment burden among people with HIV-1 infection. This retrospective study included Medicaid claims data from patients with ≥1 antiretroviral (ARV) claim between 2016 and 2017 (most recent claim defined the index date), ≥1 HIV diagnosis within 1 yr before index, age ≥18 years at first HIV diagnosis and <65 years at index, ≥12 mo of continuous eligibility before index, and no history of HIV-2 infection. Comorbidities, concomitant medication use, and pill burden were assessed in the 4 years before index. Analyses were stratified by patient age and treatment experience. Among 3456 patients, the mean (standard deviation [SD]) age was 47.1 (10.4) years; the majority were black (55%) and men (63%). In general, the prevalence of comorbidities increased from the fourth year to the first year before index and included cardiovascular disease (28-40%), hypertension (24-37%), hyperlipidemia (12-17%), and asthma/chronic obstructive pulmonary disease (13-19%). Concomitant medication use corresponding to these comorbidities slightly increased over time. In the year before index, mean (SD) daily pill burden was 2.1 (1.4) for ARVs and 5.9 (5.9) for non-ARVs. Older age and prior treatment experience were associated with higher rates of comorbidities and greater pill burden. In people with HIV infection, comorbidities and concomitant medication use increased with age, supporting considerations for streamlined ARV regimens highlighted in treatment guidelines. Current Medical Research and Opinion published new progress about Aging, animal. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Formula: C19H34O2.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Westerhaus, Felix A.; Jagadeesh, Rajenahally V.; Wienhoefer, Gerrit; Pohl, Marga-Martina; Radnik, Joerg; Surkus, Annette-Enrica; Rabeah, Jabor; Junge, Kathrin; Junge, Henrik; Nielsen, Martin; Brueckner, Angelika; Beller, Matthias published the artcile< Heterogenized cobalt oxide catalysts for nitroarene reduction by pyrolysis of molecularly defined complexes>, Computed Properties of 112-63-0, the main research area is aromatic amine preparation; hydrogenation nitroarene heterogeneous cobalt oxide catalyst.

Molecularly well-defined homogeneous catalysts are known for a wide variety of chem. transformations. The effect of small changes in mol. structure can be studied in detail and used to optimize many processes. However, many industrial processes require heterogeneous catalysts because of their stability, ease of separation, and recyclability, but these are more difficult to control on a mol. level. Here, we describe the conversion of homogeneous cobalt complexes into heterogeneous cobalt oxide catalysts via immobilization and pyrolysis on activated carbon. The catalysts thus produced are useful for the industrially important reduction of nitroarenes to anilines. The ligand indirectly controls the selectivity and activity of the recyclable catalyst and catalyst optimization can be performed at the level of the solution-phase precursor before conversion into the active heterogeneous catalyst.

Nature Chemistry published new progress about Aromatic amines Role: SPN (Synthetic Preparation), PREP (Preparation). 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Computed Properties of 112-63-0.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Grosmann, Mikkel T.; Andrade, Thalles A.; Bitonto, Luigi di; Pastore, Carlo; Corazza, Marcos L.; Tronci, Stefania; Errico, Massimiliano published the artcile< Hydrated metal salt pretreatment and alkali catalyzed reactive distillation: A two-step production of waste cooking oil biodiesel>, Related Products of 112-63-0, the main research area is potassium hydroxide biodiesel waste cooking oil kinetic reactive distillation.

In this work, a novel method was proposed for the conversion of waste cooking oil into biodiesel. A two-step approach based on a pretreatment with AlCl3•6H2O to convert FFA into the relevant Me esters, followed by the complete transesterification of glycerides, under KOH catalysis in a reactive distillation column, was considered. The pretreatment with AlCl3•6H2O allowed to obtain two different phases: an oily phase, rich in FAME and triacylglycerols and with a very limited content of water (100 ppm), and residual FFA (1 mgKOH /goil), and a methanol phase, in which most of the catalyst, water and monoacylglycerols were dissolved in. The esterified stream was characterized by its composition and used to obtain new kinetic parameters to be used in the setting of the reactive distillation The reactive distillation column was proved to be efficient in obtaining a biodiesel stream with a purity requirement conform to the EN14214 standards The transesterification step was characterized by a sp. heating requirement of 701.3 kJ per kg of biodiesel produced.

Chemical Engineering and Processing published new progress about Biodiesel fuel. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Related Products of 112-63-0.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

de Marcellus, Charles; Tauziede-Espariat, Arnault; Cuinet, Aurelie; Pasqualini, Claudia; Robert, Matthieu P.; Beccaria, Kevin; Puget, Stephanie; Boddaert, Nathalie; Figarella-Branger, Dominique; De Carli, Emilie; Bourdeaut, Franck; Leblond, Pierre; Fouyssac, Fanny; Andre, Nicolas; Bertozzi, Anne I.; Butel, Thibaut; Dufour, Christelle; Valteau-Couanet, Dominique; Varlet, Pascale; Grill, Jacques published the artcile< The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients>, Quality Control of 112-63-0, the main research area is irinotecan bevacizumab anticancer agent KIAA1549 low grade glioma children; Bevacizumab; Children; Irinotecan; Low grade glioma.

At least half of children with low-grade glioma (LGG) treated with first line chemotherapy experience a relapse/progression and may therefore need a second-line chemotherapy. Irinotecan-bevacizumab has been recommended in this setting in France after encouraging results of pilot studies. We performed a retrospective anal. to define the efficacy, toxicity and predictors for response to the combination on a larger cohort. We reviewed the files from children < 19 years of age with progressive or refractory LGG treated between 2009 and 2016 in 7 French centers with this combination. In 72 patients (median age 7.8 years [range 1-19]) received a median of 16 courses (range 3-30). The median duration of treatment was 9 mo (range 1.4-16.2). 96% of patients experienced at least disease stabilization. The 6-mo and 2-yr progression-free survivals (PFS) were 91.7% [IC 95% 85.5-98.3] and 38.2% [IC 95% 28.2-51.8] resp. No progression occurred after treatment in 18 patients with a median follow-up of 35.6 mo (range 7.6-75.9 mo). Younger patients had a worse PFS (p = 0.005). Prior chemoresistance, NF1 status, duration of treatment, histopathol. or radiol. response did not predict response. The most frequent toxicities related to bevacizumab included grades 1-2 proteinuria in 21, epistaxis in 10, fatigue in 12 and hypertension in 8 while gastro-intestinal toxicity was the most frequent side effect related to irinotecan. Bevacizumab-irinotecan has the potential of disease control clin. and radiog. in children with recurrent LGG whatever their previous characteristics; in many cases however these responses are not sustained, especially in younger children. Journal of Neuro-Oncology published new progress about Aging, animal. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Quality Control of 112-63-0.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Zhou, Li; Yang, Yue; Si, Lu; Chi, Zhihong; Sheng, Xinan; Lian, Bin; Wang, Xuan; Tang, Bixia; Mao, Lili; Yan, Xieqiao; Li, Siming; Bai, Xue; Guo, Jun; Cui, Chuanliang published the artcile< Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy>, Application In Synthesis of 112-63-0, the main research area is .

Treatment for advanced melanoma after progression on immunotherapy is limited. This phase II trial (NCT03422445) was conducted to evaluate the efficacy and safety of apatinib plus temozolomide in patients with advanced melanoma after failure of immunotherapy. Patients with unresectable stage III or stage IV melanoma after progression on immunotherapy were treated with temozolomide 300 mg on days 1-5 and apatinib 500 mg daily every 28-day cycle until disease progression or intolerable toxicities. Besides immunotherapy, prior chemotherapy, targeted therapy, and clin. trials were allowed. The primary endpoint was progression-free survival. Secondary endpoints were objective response rate, disease control rate, overall survival, and safety. Of 29 patients, 28 (96.6%) had metastatic diseases, and the predominant subtypes were mucosal [12 (41.4%)] and acral melanoma [eight (27.6%)]. Five (17.2%) patients showed BRAF, CKIT, or NRAS mutation. Five achieved confirmed partial response, with an objective response rate of 17.2%. The disease control rate was 82.8%. The median progression-free survival was 5.0 mo [95% confidence interval (CI): 4.7-5.3], and the median overall survival was 10.1 mo (95% CI: 5.1-15.0). Grade 3-4 treatment-related adverse events included proteinuria [four (13.8%)], thrombocytopenia [two (6.9%)], hypertension [one (3.4%)], and hyperbilirubinemia [one (3.4%)]. No treatment-related death occurred. Apatinib plus temozolomide demonstrated promising efficacy and manageable safety profile in patients with advanced melanoma after progression on immunotherapy.

Melanoma Research published new progress about 112-63-0. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Application In Synthesis of 112-63-0.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Kim, Jung Ho; Jiamsakul, Awachana; Kiertiburanakul, Sasisopin; Huy, Bui Vu; Khusuwan, Suwimon; Kumarasamy, Nagalingeswaran; Ng, Oon Tek; Ly, Penh Sun; Lee, Man-Po; Chan, Yu-Jiun; Gani, Yasmin Mohamed; Azwa, Iskandar; Avihingsanon, Anchalee; Merati, Tuti Parwati; Pujari, Sanjay; Chaiwarith, Romanee; Zhang, Fujie; Tanuma, Junko; Do, Cuong Duy; Ditangco, Rossana; Yunihastuti, Evy; Ross, Jeremy; Choi, Jun Yong; on behalf of IeDEA Asia-Pacific published the artcile< Patterns and prognosis of holding regimens for people living with HIV in Asian countries>, Application In Synthesis of 112-63-0, the main research area is lamivudine zidovudine antiretroviral agent prognosis HIV infection.

The use of holding regimens for people living with HIV (PLWH) without effective antiretroviral options can have effects on outcomes and future treatment options. We aimed to investigate the use of holding regimens for PLWH in Asian countries. Data from adults enrolled in routine HIV care in IeDEA Asia-Pacific cohorts were included. Individuals were considered to be on holding regimen if they had been on combination antiretroviral therapy for at least 6 mo, had two confirmed viral loads (VL) ≥1000 copies/mL, and had remained on the same medications for at least 6 mo. Survival time was analyzed using Fine and Gray’s competing risk regression. Factors associated with CD4 changes and VL <1000 copies/mL were analyzed using linear regression and logistic regression, resp. A total of 425 PLWH (72.9% male; 45.2% high-income and 54.8% low-to-middle-income country) met criteria for being on a holding regimen. From high-income countries, 63.0% were on protease inhibitors (PIs); from low-to-middle-income countries, 58.4% were on non-nucleoside reverse transcriptase inhibitors (NNRTIs); overall, 4.5% were on integrase inhibitors. The combination of lamivudine, zidovudine, and efavirenz was the most commonly used single regimen (n = 46, 10.8%), followed by lamivudine, zidovudine, and nevirapine (n = 37, 8.7%). Forty-one PLWH (9.7%) died during follow-up (mortality rate 2.0 per 100 person-years). Age >50 years compared to age 31-40 years (sub-hazard ratio [SHR] 3.29, 95% CI 1.45-7.43, p = 0.004), and VL ≥1000 copies/mL compared to VL <1000 copies/mL (SHR, 2.14, 95% CI 1.08-4.25, p = 0.029) were associated with increased mortality, while higher CD4 counts were protective. In our Asia regional cohort, there was a diversity of holding regimens, and the patterns of PI vs. NNRTI use differed by country income levels. Considering the high mortality rate of PLWH with holding regimen, efforts to extend accessibility to addnl. antiretroviral options are needed in our region. PLoS One published new progress about Antiviral agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Application In Synthesis of 112-63-0.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Dash, Pragyanditi; Janni, Manojkumar; Peruncheralathan, S. published the artcile< Trideuteriomethoxylation of Aryl and Heteroaryl Halides>, Recommanded Product: (9Z,12Z)-Methyl octadeca-9,12-dienoate, the main research area is trideuteriomethoxylation aryl heteroaryl halide perdeuteriomethanol palladium catalyst; ether trideuteriomethyl preparation.

Direct access to trideuteriomethoxylated aromatic and heteroaromatic compounds has been developed. Various aryl and heteroaryl halides underwent d3-methoxylation under mild reaction conditions by using a catalyst system composed of the com. available monodentate phosphane ligand tBuXPhos and Pd(OAc)2. Inexpensive CD3OD served as an efficient trideuteriomethoxylating agent.

European Journal of Organic Chemistry published new progress about Aryl bromides Role: RCT (Reactant), RACT (Reactant or Reagent). 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Recommanded Product: (9Z,12Z)-Methyl octadeca-9,12-dienoate.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

di Bitonto, Luigi; Locaputo, Vito; D’Ambrosio, Valeria; Pastore, Carlo published the artcile< Direct Lewis-Bronsted acid ethanolysis of sewage sludge for production of liquid fuels>, Safety of (9Z,12Z)-Methyl octadeca-9,12-dienoate, the main research area is liquid fuel sewage sludge ethanolysis catalytic wastewater treatment.

Ethanolysis carried out under Lewis-Bronsted acid catalysis was investigated as a possible process to valorize the organic fraction of urban sewage sludge, with the aim of selectively obtaining liquid biofuels. In a single reactive step, the conversion of lipids into fatty acid Et esters, of carbohydrates into Et levulinate, furanic compounds and Et glycosides and of proteins into Et ester of amino acids was achieved. The optimization of reactive conditions was conducted using pure chems. as model compounds The effect of the co-presence of water was also considered. Then, real samples of sewage sludge (as dried and wet centrifuged samples) were reacted in ethanol in the presence of the appropriate combination of homogeneous Lewis-Bronsted acid catalysts, namely 1%wt aluminum chloride hexahydrate and sulfuric acid respect to ethanol. After 6 h at 453 K, 99% of lipids and almost 60% of initial complex sugars were effectively converted into the abovementioned target products. Conversions and yields were quite similar to those obtained by reacting pure compounds singularly, confirming the robustness of the process and its applicability to differently composed sludge. At the end of the reaction, products were easily recovered and purified from the alc. phase, whereas only a very limited amount of solids remain as inert materials. Final refined biofuels have high calorific values (37 and 40 MJ kg-1) and actually represent the 68.5 and 59.2% of the initial energy content of starting sludge, resp. This strategy combines valorization of the starting organic fraction of sewage sludge and a considerable reduction of final solid waste (in a stabilized form) to be disposed of. Finally, through a preliminary feasibility study, this acid ethanolysis resulted in a competitive alternative to the anaerobic digestion of mixed sewage sludge to obtain biofuels.

Applied Energy published new progress about Biofuels. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Safety of (9Z,12Z)-Methyl octadeca-9,12-dienoate.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Lee, Bongyong; Mohamad, Iqbal; Pokhrel, Rudramani; Murad, Rabi; Yuan, Menglang; Stapleton, Stacie; Bettegowda, Chetan; Jallo, George; Eberhart, Charles G.; Garrett, Timothy; Perera, Ranjan J. published the artcile< Medulloblastoma cerebrospinal fluid reveals metabolites and lipids indicative of hypoxia and cancer-specific RNAs>, Safety of (9Z,12Z)-Methyl octadeca-9,12-dienoate, the main research area is RNA lipid cerebrospinal fluid hypoxia medulloblastoma; Circular RNA; Lipidomics; Medulloblastoma; Metabolomics; TCA; Transcriptomics.

Medulloblastoma (MB) is the most common malignant brain tumor in children. There remains an unmet need for diagnostics to sensitively detect the disease, particularly recurrences. Cerebrospinal fluid (CSF) provides a window into the central nervous system, and liquid biopsy of CSF could provide a relatively non-invasive means for disease diagnosis. There has yet to be an integrated anal. of the transcriptomic, metabolomic, and lipidomic changes occurring in the CSF of children with MB. CSF samples from patients with (n = 40) or without (n = 11; no cancer) MB were subjected to RNA-sequencing and high-resolution mass spectrometry to identify RNA, metabolite, and lipid profiles. Differentially expressed transcripts, metabolites, and lipids were identified and their biol. significance assessed by pathway anal. The DIABLO multivariate anal. package (R package mixOmics) was used to integrate the mol. changes characterizing the CSF of MB patients. Differentially expressed transcripts, metabolites, and lipids in CSF were discriminatory for the presence of MB but not the exact mol. subtype. One hundred and ten genes and ten circular RNAs were differentially expressed in MB CSF compared with normal, representing TGF-β signaling, TNF-α signaling via NF-kB, and adipogenesis pathways. Tricarboxylic acid cycle and other metabolites (malate, fumarate, succinate, α-ketoglutarate, hydroxypyruvate, N-acetyl-aspartate) and total triacylglycerols were significantly upregulated in MB CSF compared with normal CSF. Although separating MBs into subgroups using transcriptomic, metabolomic, and lipid signatures in CSF was challenging, we were able to identify a group of omics signatures that could sep. cancer from normal CSF. Metabolic and lipidomic profiles both contained indicators of tumor hypoxia. Our approach provides several candidate signatures that deserve further validation, including the novel circular RNA circ_463, and insights into the impact of MB on the CSF microenvironment.

Acta Neuropathologica Communications published new progress about 14-3-3 Protein YWHAG Role: BSU (Biological Study, Unclassified), BIOL (Biological Study). 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Safety of (9Z,12Z)-Methyl octadeca-9,12-dienoate.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics